SCHEMBL24257623

SCHEMBL24257623

Cc1c(-c2ccc3ccccc3c2)cnc(C#N)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.43
ADORA2A P29274 2/20 0.41
ADORA1 P30542 2/20 0.41
KDM4E B2RXH2 2/20 0.40
KDR P35968 1/20 0.39
CYP11B1 P15538 2/20 0.39
CYP11B2 P19099 2/20 0.39
GSTP1 P09211 1/20 0.38
ALDH1A1 P00352 2/20 0.38
POLB P06746 1/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP3A4 P08684 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
IKBKB O14920 1/20 0.36
CYP2C19 P33261 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30546851 1.00 DHFR (0.43) DHFRADORA2AADORA1KDM4EKDR
SCHEMBL24257735 0.86 ALOX15 (0.48) CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4
SCHEMBL30546884 0.85 POLB (0.48) ADORA2ACYP11B2ALDH1A1POLBCYP1A2
SCHEMBL24257739 0.85 POLB (0.48) ADORA2ACYP11B2ALDH1A1POLBCYP1A2
SCHEMBL30453344 0.83 CYP1A2 (0.39) KDM4EPOLBCYP1A2
SCHEMBL24257719 0.83 CYP1A2 (0.39) KDM4EPOLBCYP1A2
SCHEMBL30454648 0.81 DHFR (0.44) DHFRADORA2AADORA1KDM4EALDH1A1
SCHEMBL24257698 0.81 DHFR (0.44) DHFRADORA2AADORA1KDM4EALDH1A1
SCHEMBL24257731 0.81 LRRK2 (0.42) ADORA2AADORA1KDM4ECYP11B1CYP11B2
SCHEMBL24257773 0.80 BTK (0.44) ADORA2AADORA1ALDH1A1POLBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
CN-116670131-A PHD inhibitor compounds, compositions, and methods of use 阿克比治疗有限公司 2023-08-29 CN disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 DHFR 1618/4885ADORA2A 4872/4885ADORA1 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.